Publicaciones en las que colabora con José Luis González Larriba (12)

2010

  1. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non - small-cell lung cancer

    Journal of Clinical Oncology, Vol. 28, Núm. 19, pp. 3138-3145

2005

  1. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 16, Núm. 7, pp. 1081-1086

2004

  1. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 5, Núm. 6, pp. 360-365

2003

  1. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial

    Journal of Clinical Oncology, Vol. 21, Núm. 17, pp. 3207-3213

2001

  1. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 19, Núm. 4, pp. 1071-1077

1999

  1. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations

    Journal of Clinical Oncology, Vol. 17, Núm. 6, pp. 1786-1793

  2. Randomized phase III study of Gemcitabine-cisplatin versus Etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

    Pneumologie, Vol. 53, Núm. 5

  3. Randomized phase III study of gemcitabine-cisplatin versus etoposide- cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 17, Núm. 1, pp. 12-18

1997

  1. Six year follow up of the European multicentre randomised study comparing navelbine (NVB) alone vs NVB + cisplatin (CDDP) vs vindesine (VDS) + CDDP in 612 patients (PTS) with advanced non-small cell lung cancer (NSCLC)

    Thorax, Vol. 52, Núm. SUPPL. 6

1995

  1. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer

    Annals of Oncology

  2. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity

    Seminars in Oncology, Vol. 22, Núm. 6 SUPPL. 14, pp. 12-18

1994

  1. ESTUDIO CON REPARTO ALEATORIO DE NAVELBINA FRENTE A NAVELBINA Y CISPLATINO FRENTE A VINDESINA Y CISPLATINO EN EL TRATAMIENTO DEL CARCINOMA PULMONAR NO MICROCELULAR INOPERABLE. RESULTADOS DE UN ESTUDIO MULTICENTRICO EUROPEO INCLUYENDO 612 PACIENTES

    Revista Clinica Espanola, Vol. 194, Núm. 11, pp. 953-959